US RFID in Pharmaceuticals Market Report Scope & Overview:

US RFID in Pharmaceuticals Market was valued at USD 1.66 Billion in 2025 and is expected to reach USD 3.39 Billion by 2035, growing at a CAGR of 7.40% from 2026-2035.

The US RFID in Pharmaceuticals Market is advancing as drug manufacturers and large pharmacy chains expand item-level tagging to satisfy Drug Supply Chain Security Act verification requirements and reduce diversion risk across increasingly complex distribution networks nationwide. Zebra Technologies’ deployment with Texas Children’s Hospital, which reported USD 14 million in annual medication cost savings, is reinforcing hospital pharmacy confidence in RFID-driven inventory accuracy programs across every U.S. sub-region. Growing biologics and specialty drug manufacturing is widening demand for sensor-enabled tags capable of continuous cold-chain condition monitoring from production through last-mile delivery. Continued investment by tag, reader, and middleware suppliers in sterilization-compatible and chipless product lines is further broadening adoption across vials, syringes, and other sensitive packaging formats nationwide.

⮞Having closed its DSCSA stabilization window on May 27, 2026, the country is now moving into full enforcement of enhanced drug distribution security requirements. The U.S. was identified as the largest contributor to North America, itself the second-largest global RFID in pharmaceuticals region, while Asia Pacific was named the fastest-growing region worldwide.

US RFID in Pharmaceuticals Market Segment Analysis

• By Component, RFID Tags dominate the US RFID in Pharmaceuticals Market with 47.35% share in 2025; RFID Middleware is expected to grow at the fastest CAGR of 10.15% from 2026–2035.

• By Type, Chipped RFID dominates the US RFID in Pharmaceuticals Market with 73.20% share in 2025; Chipless RFID is expected to grow at the fastest CAGR of 10.05% from 2026–2035.

• By Application, Drug Tracing & Authentication dominates the US RFID in Pharmaceuticals Market with 53.80% share in 2025; Drug Quality & Condition Monitoring is expected to grow at the fastest CAGR of 10.50% from 2026–2035.

• By End User, Drug Manufacturers dominate the US RFID in Pharmaceuticals Market with 49.80% share in 2025; Retail & E-Pharmacies are expected to grow at the fastest CAGR of 10.60% from 2026–2035.

By Component, RFID Tags Dominate the US RFID in Pharmaceuticals Market, RFID Middleware Grows Fastest

RFID tags hold the largest U.S. component share given their low unit cost, straightforward integration into existing packaging lines, and mandatory status under item-level serialization requirements for prescription drugs across the country. Leading suppliers including Avery Dennison, CCL Industries, and Tageos have scaled high-volume inlay production to meet surging demand from drug manufacturers racing to satisfy Drug Supply Chain Security Act verification deadlines nationwide. Continued cost declines in chip-based and chipless tag manufacturing are reinforcing tags as the dominant revenue contributor across nearly every pharmaceutical packaging format even as middleware and software categories expand at a faster underlying rate through the forecast window.

RFID middleware is forecast to grow fastest as drug manufacturers and distributors scale item-level verification programs that require reliable data capture, filtering, and transmission between readers and enterprise track-and-trace systems nationwide. Growing integration between on-site RFID infrastructure and cloud-based EPCIS analytics platforms is converting latent middleware demand into sustained software licensing and service growth faster than any other component category across the country. Expanding hospital and pharmacy chain deployments, each requiring tailored middleware configuration, are further reinforcing this growth pattern through the remainder of the 2026-2035 forecast period as integration requirements become more standardized nationwide.

By Type, Chipped RFID Dominates the US RFID in Pharmaceuticals Market, Chipless RFID Grows Fastest

Chipped RFID tags remain the dominant type given their established read-range performance, mature supplier ecosystem, and broad compatibility with existing pharmaceutical serialization and track-and-trace infrastructure built up over more than a decade nationwide. NXP Semiconductors and Impinj continue to supply the chip platforms underpinning most drug manufacturer and distributor deployments, reinforcing chipped RFID as the default technology choice across nearly every application category in the country. This structural position is expected to persist through the remainder of the forecast period even as chipless alternatives gain traction in cost-sensitive, high-volume tagging use cases across the broader pharmaceutical packaging landscape.

Chipless RFID is growing fastest as suppliers including Avery Dennison introduce sterilization-compatible inlay portfolios suited to vials, syringes, and other harsh-environment items where chip-based tags face cost or durability constraints nationwide. Falling production costs for printed and chipless formats are converting latent demand among smaller drug manufacturers and packaging converters into sustained volume growth faster than any other type category across the country. Continued expansion of chipless tag applications into blister packs and secondary packaging is expected to further reinforce this above-average growth trajectory through the remainder of the 2026-2035 forecast window as adoption broadens.

By Application, Drug Tracing & Authentication Dominates the US RFID in Pharmaceuticals Market, Drug Quality & Condition Monitoring Grows Fastest

Drug tracing and authentication remains the largest application given direct regulatory pressure from the Drug Supply Chain Security Act, which requires manufacturers and distributors to maintain verifiable chain-of-custody records at the item level nationwide. Established serialization infrastructure built by major drug manufacturers over the past decade continues to anchor this application as the dominant revenue contributor across nearly every RFID deployment in the country. As enforcement steps up nationwide following the close of the stabilization window, tracing and authentication is expected to stay the leading driver of tag and reader purchasing decisions for the rest of the forecast period.

Drug quality and condition monitoring is set to post the fastest growth as biologics and other temperature-sensitive therapies drive demand for sensor-enabled tags capable of continuous cold-chain tracking from manufacturing through last-mile delivery nationwide. Growing biologics manufacturing investment across the country is accelerating adoption of condition-monitoring RFID among drug manufacturers seeking to reduce spoilage-related losses and regulatory exposure. Rising integration of sensor data with cloud analytics platforms is expected to further reinforce this application’s above-average growth trajectory through the remainder of the 2026-2035 forecast window as biologics volumes continue expanding nationwide.

By End User, Drug Manufacturers Dominate the US RFID in Pharmaceuticals Market, Retail & E-Pharmacies Grow Fastest

Drug manufacturers remain the largest end user given their direct regulatory obligation to serialize and verify products at the point of manufacture under the Drug Supply Chain Security Act across the country. Point-of-manufacture tagging programs adopted by major pharmaceutical producers continue to anchor this end-user category as the dominant revenue contributor across nearly every RFID component and application nationwide. Established supplier relationships between tag, reader, and middleware vendors and large drug manufacturers are expected to keep this group the primary purchaser of RFID infrastructure through the remainder of the forecast period as enforcement intensifies across every sub-region.

Retail and e-pharmacies are growing fastest as online prescription fulfillment expands and chains seek RFID-enabled inventory accuracy and anti-diversion controls across increasingly distributed fulfillment networks nationwide. Zebra Technologies’ hospital pharmacy deployment results are encouraging similar retail and e-pharmacy adoption as chains look to replicate comparable inventory and cost-saving outcomes. Growing consumer reliance on online pharmacy ordering is expected to further reinforce this end user’s above-average growth trajectory through the remainder of the 2026-2035 forecast period as digital fulfillment volumes continue to climb across the country.

Regional Analysis

South US RFID in Pharmaceuticals Market Insights

The South region dominated the US RFID in Pharmaceuticals Market with the highest revenue share of about 37.85% in 2025, supported by the concentration of major pharmaceutical manufacturing and distribution facilities across Texas, North Carolina, and surrounding states. Growing biologics and specialty drug manufacturing investment across the region continues to anchor the South as the dominant revenue contributor to the national market. Established distribution infrastructure linking Gulf Coast ports to national pharmacy networks further reinforces the region’s leading position, and the South is expected to stay the country’s primary revenue engine for the remainder of the forecast period as enforcement steps up nationwide.

Continued expansion of item-level serialization programs among major drug manufacturers headquartered across the South, combined with sustained hospital and retail pharmacy modernization, reinforces the region’s dominance within the broader U.S. market. Ongoing supplier investment in regional distribution and technical support infrastructure is also easing adoption barriers for smaller manufacturers operating across the region. This structural position is expected to continue shaping purchasing and deployment decisions through the remainder of the forecast period as enforcement and modernization efforts proceed in parallel across Texas, North Carolina, and neighboring states.

West US RFID in Pharmaceuticals Market Insights

The West region is expected to grow at the fastest CAGR of about 8.80% from 2026–2035, facilitated by California’s concentration of biologics and specialty drug manufacturers and growing investment in sensor-enabled cold-chain monitoring technology across the region’s pharmaceutical supply chain. Rising adoption of RFID-enabled inventory programs among West Coast hospital networks and retail pharmacy chains is reinforcing the region’s above-national growth trajectory. This dynamic is expected to persist through the remainder of the 2026-2035 forecast window as biotechnology manufacturing investment across California and Washington continues to expand.

Moreover, continued investment by major RFID suppliers in West Coast distribution and technical support infrastructure, combined with growing biotechnology manufacturing investment across California, is supporting faster-than-average volume growth across the region through the forecast period. Expanding retail and e-pharmacy fulfillment operations centered in West Coast metropolitan areas are expected to further reinforce the region’s above-national growth rate through 2035. Continued supplier coordination with regional hospital networks is expected to reinforce this pattern through the remainder of the decade as deployment practices continue to mature across the broader western United States.

Midwest US RFID in Pharmaceuticals Market Insights

The Midwest region held a steady revenue share of about 21.65% of the US RFID in Pharmaceuticals Market in 2025, supported by established pharmaceutical manufacturing clusters across Illinois, Indiana, and Ohio and a long-standing concentration of hospital and health-system pharmacy networks. Growing investment in point-of-manufacture tagging among regional drug manufacturers continues to reinforce the Midwest’s position as a consistent contributor to the national market. Established logistics infrastructure linking the region’s manufacturing base to national distribution networks further supports steady volume growth through the remainder of the forecast period across the broader Midwest pharmaceutical supply chain.

Continued modernization of hospital pharmacy inventory systems across Illinois, Indiana, and Ohio, combined with growing supplier investment in regional technical support infrastructure, is supporting steady volume growth across the Midwest through the forecast period. Expanding biologics and specialty drug manufacturing tied to the region’s established pharmaceutical production base is expected to further reinforce this steady contribution through 2035. Continued collaboration between regional drug manufacturers and RFID suppliers on technical specifications is expected to sustain this trajectory through the remainder of the decade across the broader Midwest market.

Northeast US RFID in Pharmaceuticals Market Insights

The Northeast region accounted for about 16.15% of the US RFID in Pharmaceuticals Market in 2025, supported by a concentrated cluster of biologics manufacturers and research hospitals across Massachusetts, New Jersey, and New York with strong existing serialization infrastructure. Established relationships between regional drug manufacturers and major tag and middleware suppliers continue to support steady adoption of item-level verification programs across the Northeast. Growing investment in cold-chain condition monitoring tied to the region’s biologics manufacturing concentration is expected to support continued volume growth through the remainder of the forecast period across the broader Northeast pharmaceutical market.

Continued expansion of biologics and specialty drug manufacturing across Massachusetts and New Jersey, combined with sustained hospital pharmacy modernization across New York, is supporting ongoing RFID adoption across the Northeast through the forecast period. Expanding retail and e-pharmacy fulfillment operations centered in the region’s dense metropolitan markets are expected to further support this contribution through 2035. Continued supplier investment in regional distribution and technical support infrastructure is expected to reinforce this pattern through the remainder of the decade across the broader Northeast pharmaceutical supply chain.

Market Dynamics

Growth Drivers: DSCSA enforcement and expanding biologics manufacturing are increasing demand for item-level and cold-chain RFID tagging.

Continued enforcement of Drug Supply Chain Security Act serialization milestones is pushing drug manufacturers and distributors across the country to accelerate item-level RFID verification investment ahead of stabilization-period deadlines. Growing biologics and specialty drug manufacturing is widening demand for sensor-enabled tags capable of continuous cold-chain condition monitoring from production through last-mile pharmacy delivery nationwide. Falling tag production costs and expanding chipless product portfolios are further easing adoption among smaller manufacturers and packaging converters previously deterred by cost. Hospital pharmacy automation programs, reinforced by reported cost-saving outcomes at deployments such as Texas Children’s Hospital, are expected to sustain this trajectory through the remainder of the forecast period.

Restraints: High integration costs and RF performance limitations near metal and liquids continue to complicate deployment decisions.

High integration and validation costs continue to complicate RFID adoption decisions for smaller drug manufacturers and distributors nationwide, particularly where legacy packaging lines require significant retrofitting to accommodate tagging equipment. Reduced RF read performance near metal shelving and liquid-filled containers remains a persistent technical constraint for pharmacy and distribution-center deployments, requiring careful site-specific engineering across every U.S. sub-region. Data security and standards fragmentation across different reader and middleware platforms add further complexity to enterprise-wide rollout decisions. The fact that the Drug Supply Chain Security Act does not explicitly mandate RFID technology continues to leave some manufacturers evaluating alternative serialization approaches.

Opportunities: Automated bulk verification and sensor-enabled cold-chain monitoring create substantial long-term growth potential.

Expanding demand for automated bulk verification at distribution centers and returns-processing points is opening substantial new RFID deployment opportunities well beyond traditional point-of-manufacture tagging nationwide. Growing adoption of sensor-enabled tags capable of continuous temperature and condition monitoring is creating new product lines tailored to biologics, vaccines, and other temperature-sensitive therapies moving through increasingly complex distribution networks. Continued supplier investment in sterilization-compatible and chipless formats is also expected to broaden RFID use into vials, syringes, and other historically difficult-to-tag packaging formats, supporting more sustainable long-term category growth across the country through the remainder of the forecast period.

⮞In 2025, Impinj expanded its reader chip portfolio to support higher-density tag reads, a development expected to ease large-scale distribution-center verification across the country.

US RFID in Pharmaceuticals Market key players are:

• Avery Dennison Corporation

• Zebra Technologies Corporation

• Impinj, Inc.

• CCL Industries Inc. (Smartrac)

• Fresenius Kabi AG

• Checkpoint Systems, Inc.

• NXP Semiconductors N.V.

• SATO Holdings Corporation

• Schreiner MediPharm

• Tageos SAS

• GAO RFID Inc.

• Invengo Technology Corp.

• Honeywell International Inc.

• Siemens AG

• Bluesight, Inc.

• Paragon ID Plc

• Turck Vilant Systems

• p-Chip Corporation

• Confidex Ltd.

• Mojix, Inc.

US RFID in Pharmaceuticals Market Report Scope: